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Abbreviations Used in This Thesis 
 
AMPK      5' AMP-Activated Protein Kinase 
BSA      Bovine Serum Albumin 
cAMP      Cyclic Adenosine Monophosphate 
cDNA      Complementary DNA 
CS      Calf Serum 
DEPC Water     Diethylpyrocarbonate Water 
DMEM     Dulbecco Modified Eagle Medium 
DMSO      Dimethyl Sulfoxide 
DNA      Deoxy-Ribonucleic Acid 
DPP IV     Dipeptidyl Peptidase IV 
DPP6      Dipeptidyl Peptidase 6 
DPP8      Dipeptidyl Peptidase 8 
DPP9      Dipeptidyl Peptidase 9 
DPP10      Dipeptidyl Peptidase 10 
EDTA      Ethylenediaminetetraacetic acid 
ELISA      Enzyme Linked Immunosorbent Assay 
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FAP      Fibroblast Activating Protein 
FBS      Fetal Bovine Serum 
GIP      Gastric Inhibitory Peptide 
GLP-1      Glucagon-like Peptide-1 
HbA1c      Glycated Hemoglobin A1c 
HBSS      Hanks Buffered Saline Solution 
HCl      Hydrochloric Acid 
HNF-1α     Hepatocyte Nuclear Factor-1α 
IEW      Ion Exchange Water 
IGT      Impaired Glucose Tolerance 
MAPK      Mitogen-Activated Protein Kinases 
NGT      Normal Glucose Tolerance 
OGTT      Oral Glucose Tolerance Test 
PBS      Phosphate Buffered Saline 
PCR      Polymerase Chain Reaction 
PPIA      peptidylprolyl isomerase A 
rRNA      Ribosomal RNA 
RNA      Ribonucleic Acid 
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RT      Reverse Transcription 
RT-PCR     Real Time PCR 
STZ      Streptozotocin 
TNF-α      Tumor Necrosis Factor-α 
TRPV4     Transient Receptor Potential Vanilloid 4 
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1.  Introduction 
Dipeptidyl peptidase IV (DPP IV) is a ubiquitously expressed transmembrane glycoprotein.  It 
is a glycosylated homodimer that is 766 amino acids in length. The protein has a short 
cytoplasmic tail of 6 amino acids; a transmembrane domain of 29 amino acids and a 
catalytically active part of 731 amino acids [1]. DPP IV exists as intracellular and surface-
expressed [2] and also as a serum soluble form [3]. The serum soluble form is identical to the 
surface-expressed form, except that, it lacks the short cytoplasmic tail and the transmembrane 
domain. Both the surface-expressed form and the serum soluble form are equally active because 
the catalytic part of the protein lies outside the cell. DPP IV is a serine protease that inactivates 
the insulinotropic activity of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide 
(GIP) within a couple of minutes of secretion [4, 5]. GLP-1 and GIP are incretin hormones that 
are involved in regulating postprandial nutrient hemostasis. These peptide hormones increase 
the meal induced insulin secretion from the pancreatic β-cells [6].  
DPP IV is primarily a subject of interest in diabetes whereas the other DPP IV family 
members like DPP8, DPP9 and Fibroblast Activating Protein (FAP) are a subject of interest in 
cancer [7]. Fibroblast Activating Protein is usually expressed in low levels in tissue, but gets up-
regulated under diseased conditions. However there is no reported evidence of Fibroblast 
Activating Protein being related to diabetes [8, 9]. Needless to say, all the members of DPP IV 
family are active in cleaving the incretin hormones and other peptides, but the intracellular 
location of DPP8 and DPP9 makes them enzyme activity much slower [10, 11]. Presence of two 
other catalytically inactive DPP IV members have been reported; namely DPP6 and DPP10 [12]. 
There has been no reported evidence of a connection between DPP6 and DPP10 with diabetes. 
TNF-α, interferons, retinoic acid, high insulin, glucose and hypoxia are some of the 
factors that affect the DPP IV production and release with unknown mechanisms of regulation 
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[13-16]. The serum DPP IV activity increases under conditions like non-alcoholic fatty liver 
disease, rheumatoid arthritis and inflammatory bowel disease [17]. It has also been shown that 
mouse that lacks DPP IV are resistant to obesity, insulin resistance and is also resistant to 
streptozotocin induced type 1 diabetes. The serum insulin levels are also higher in these DPP 
IV
-/-
 mice [18]. A more recent data shows that DPP IV is also a myokine and its expression 
pattern also similar to DPP IV production during adipocyte differentiation [19].  
Previous studies have shown that serum DPP IV activity increases under type 1 and 
type 2 diabetes in patients [17, 20] and in mice [21, 22]. Since under both the type of diabetes, 
glucose and serum DPP IV activity are elevated, therefore we hypothesized a possible 
connection between glucose levels and DPP IV production. A previous report on intestinal cell 
line shows a negative correlation between glucose concentrations and DPP IV [15]. Therefore, 
the increase in serum DPP IV levels under type 1 and type 2 diabetes could not be explained by 
intestinal cell-derived DPP IV. The serum DPP IV levels have been shown to be increased 
under certain metabolic syndromes like obesity and adipocyte size is positively correlated to 
serum DPP IV levels. Recent studies have shown that DPP IV is an adipokine that is produced 
from the adipocytes and acts in an autocrine and paracrine fashion to cause insulin resistance 
[13, 23]. There is an increased production of DPP IV from the visceral adipose tissue as 
compared to subcutaneous adipose tissue in case of diabetic patients. Furthermore, the DPP IV 
production from the adipocytes of lean but impaired glucose tolerance (IGT) patients is higher 
as compared to the normal glucose tolerance (NGT) patients. In case of obese diabetic patients, 
there is an increased DPP IV production from the adipocytes as compared to obese non-diabetic 
patients. The serum DPP IV levels in insulin resistant patients are also higher than the patients 
who are insulin-sensitive. DPP IV expression is positively correlated to leptin, IL-6, fasting 
plasma insulin and HbA1c levels and is negatively correlated to adiponectin levels. However, 
glucose regulation of DPP IV production in adipocytes was not clarified in any of the studies. In 
this study, we examined the effects of glucose on DPP IV production and release in adipocytes 
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under physiological and diabetic conditions. We used 3T3-L1 adipocytes as a model for in-vitro 
experiments and obtained isolated adipocytes from mice for our ex-vivo experiments.   
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2.  Experimental Requirements 
2.1  Cells 
3T3-L1 Cells: Health Science Research Resources Bank, Japanese Collection of Research 
Bioresources Cell Bank (JCRB9014), Osaka, Japan. 
2.2  Animals 
C57BL/6 Mice: 10-weeks old; SLC, Shizuoka, Japan 
2.3  Reagents 
0.25% Trypsin-EDTA       Invitrogen 
2-Propanol        Wako 
3-Isobutyl-1-methylxanthine (IBMX)     Sigma-Aldrich 
β-Mercaptoethanol       Wako 
Acetone        Wako 
Bovine Serum Albumin       Sigma-Aldrich 
Calf Serum (CS)       ICN Biomedical 
Chloroform         Wako 
Collagenase Type II       Sigma-Aldrich 
DEPC treated Water       Ambion 
Dexamethasone        Sigma-Aldrich 
Dimethyl Sulfoxide (DMSO)      Wako 
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Disodium Hydrogen Phosphate (Na2HPO4)    Wako 
Dulbecco Modified Eagle Medium (DMEM 5.5 mM glucose)  Nissui Seiyaku 
Dulbecco Modified Eagle Medium (DMEM 25 mM glucose)  Sigma-Aldrich 
Ethanol         Wako 
Fast blue BN         Sigma-Aldrich 
Fetal Bovine Serum (FBS)      Biowest 
Formalin        Wako 
Glycyl-propyl-4-methoxy-β-naphtylamide     Sigma-Aldrich 
High-Fat Diet        Research Diets 
Insulin         Sigma-Aldrich 
L-glutamine        Wako 
Normal Chow        CLEA 
Oil Red O        Sigma-Aldrich 
Penicillin G Potassium       Meiji Seika 
RNA IsoPlus        TaKaRa Bio Inc 
Sodium Bicarbonate (NaHCO3)      Wako 
Sodium Dihydrogen Phospahte (NaH2PO4)    Wako 
Streptomycin Sulfate       Meiji Seika 
Streptozotocin        Sigma-Aldrich 
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Tris          Wako 
Tryptan Blue        Life Technologies 
2.4  Primers 
DPP IV Forward: 5’-TTG TGG ATA GCA AGC GAG TTG-3’  
DPP IV Reverse: 5’-CAC AGC TAT TCC GCA CTT GAA-3’  [24] 
DPP8 Forward: 5’-ATG ATT ACC ACC CAG GAA GCG-3’  
DPP8 Reverse: 5’-ATC TCC GAC ATC TTG AAA GTG ACC-3’ [25]  
DPP9 Forward: 5’-CACGGCCTCTTGGGAAGGCTC-3’  
DPP 9 Reverse: 5’-GCGGGGGAGGGCACATGAAT-3’  
PPIA Forward: 5’-ACC GTG TTC TTC GAC ATC ACG-3’  
PPIA Reverse: 5’- CTG GCA CAT GAA TCC TGG AATA-3’ [26] 
2.5  Kits 
Blood Glucose Measurement Kit     Ascensia, Bayer 
Bradford Protein Assay Kit      Bio-Rad Laboratories 
Mouse Dipeptidyl Peptidase IV ELISA Kit    R&D systems 
2.6  Reagent Preparation 
2.6.1  DMEM Preparation 
DMEM         4.75 g 
Milli-Q Water        500 ml 
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Mix using magnetic stirrer and autoclave at 121°C for 15 min. Thereafter, add the following 
reagents by filtering. 
Sodium Bicarbonate (NaHCO3)      0.75 g 
L-glutamine        0.292 g 
Penicillin G Potassium       9 mg 
Streptomycin Sulfate       25 mg 
2.6.2  DMEM High-Glucose Preparation 
DMEM (high-glucose)       6.7 g 
Penicillin G Potassium       37.5 mg 
Streptomycin Sulfate       25 mg 
β-mercaptoethanol       2.5 μl 
Milli-Q Water        500 ml 
Mix using magnetic stirrer and filter the media through 0.22 μM membrane. 
2.6.3  Oil Red Staining Reagent Preparation 
2.6.3.1   10% Formalin (pH 7.4) 
Na2HPO4.12H2O       0.164 g 
NaH2PO4.2H2O        0.04 g 
Formalin        1 ml 
Milli-Q Water        10 ml 
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Adjusted to pH 7.4 
2.6.3.2   60% 2-Propanol 
2-Propanol        9 ml 
Milli-Q Water        6 ml 
2.6.3.3   0.3% Oil Red O (100% 2-Propanol) 
Oil Red O        30 mg 
2-Propanol        10 ml 
Shake and stock at RT. 
2.6.3.4   0.18% Oil Red O (60% 2-Propanol) 
0.3% Oil Red O        6 ml 
Milli-Q Water        4 ml 
Prepare just before using, and filter with 0.2 µM membrane. 
2.6.4  2%BSA-HBSS Preparation 
Collagenase        100 mg 
BSA         1 g 
Penicillin G Potassium       3.5 mg 
Streptomycin Sulfate       5 mg 
HBSS         50 ml 
2.6.5  Citrate Buffer Preparation 
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Citric Acid       0.26 g in 25 ml Milli-Q 
Sodium Citrate       0.365 g in 25 ml Milli-Q 
Pour citric acid solution in to sodium citrate solution and adjust pH to 4.5 Autoclave the buffer 
solution for 15 min at 121°C. 
2.6.6  Tris-HCl Buffer Preparation 
Tris         60 mg 
Milli-Q Water        50 ml 
Adjusted to pH 7.0 
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3.  Experimental Procedure 
3.1  Cell Culture 
3.1.1  Passage of 3T3-L1 cells 
3T3-L1 cells were cultured in 10%FBS-DMEM in 75cm
2
 non-coated culture flasks (IWAKI), 
under 37°C and 5% CO2. Cells were passaged at 70-80% confluence. Briefly, cells were washed 
with D-PBS twice and 2 ml of 0.25% trypsin-1mM EDTA was added and incubated for a 
minute at 37°C, 5% CO2. The flask was taken out and tapped gently and observed under 
microscope to assure all cells had removed. Cells were pipetted out into 2 ml of calf-serum and 
remaining cells inside the flask were washed with D-PBS and added up into the calf-serum 
solution. Cells were centrifuged at 175 xg for 4 min. Thereafter, the supernatant was removed 
and cells were seeded into 75 cm
2
, non-coated culture flasks at 37°C, 5% CO2. 
3.1.2  Seeding of 3T3-L1 cells 
Cells were removed from the flask as described above and were counted in a haemocytometer 
using tryptan blue. Tryptan blue helps to distinguish between live and dead cells. Cells were 
seeded at 1 x 10
5
 cells/ml in 24-well plate (Becton Dickinson) in media containing 10%FBS-
DMEM (5.5 mM or 25 mM). Each well was seeded with 0.5 ml of the cell solution and 
incubated at 37°C, 5% CO2. 
3.1.3  Induction of Differentiation 
Two days after incubation of 3T3-L1 cells in 24-well plate, differentiation was induced using 
differentiation cocktail: DMEM (5.5 or 25 mM glucose), 0.5 mM 3-isobutyl-1-methylxanthine 
(Sigma-Aldrich), 0.25 µM dexamethasone (Sigma-Aldrich) and 1 µg/ml insulin (from bovine 
pancreas, Sigma-Aldrich) for 3 days. After that period, media was changed to 10% FBS-DMEM 
(5.5 or 25 mM glucose) containing 1 µg/ml insulin only. Thereafter, media was changed every 2 
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days until day 14. Unless or otherwise stated, all experiments were carried out using adipocytes 
at day 10. 
3.1.4  Oil Red O Staining 
Oil Red O staining of lipid droplets in adipocytes was carried out as described previously [27]. 
3T3-L1 cells were cultured up to day 10 adipocytes as described earlier under both 5.5 and 25 
mM glucose conditions. Cells were washed once with 500 μl PBS and then fixed with 500 μl 
10% formalin for 10 min. Cells were washed again with 500 μl PBS and then incubated in 500 
μl 60% 2-propanol for a minute. Thereafter, cells were incubated in 500 μl 0.18% Oil Red O 
stain for 15 min. Adipocytes were then washed with 500 μl 60% 2-propanol and then washed 
with 500 μl PBS again. For measuring the lipid content, the stained Oil Red O was dissolved in 
500 μl 100% 2-propanol and incubated for 15 min. Finally, absorbance was measured at 540 nm. 
3.1.5  DPP IV Activity Staining 
DPP IV activity staining was carried out as per method described by Miyake et al with minor 
modifications [28]. 3T3-L1 cells were grown on cover slips placed inside 6-well plates under 
5.5 or 25 mM glucose conditions. On days 0, 6, 10 and 14, the coverslips were taken out and 
washed once with PBS. Cells were then fixed in formalin: PBS: cold acetone (-20 °C) = 1:35:15 
for 30-60 seconds followed by washing with water for 20-30 seconds. The coverslips were then 
dipped in a substrate solution constituting of glycyl-propyl-4-methoxy-β-naphtylamide (Sigma-
Aldrich) + fast blue BN (o-dianisidine, tetrazotized, Sigma-Aldrich) for 30 minutes at room 
temperature, protected from light. After 30 minutes, the coverslips were washed in water for 20-
30 seconds and stained with ethanol free haematoxylin for 5 minutes. Finally the coverslips 
were air-dried for 5-10 minutes and mounted on a slide. The coverslips were then pictured under 
an optical microscope. 
3.1.6  Collection of Intracellular DPP IV 
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On respective days of differentiation, cells were washed with PBS once and 500 μl of 10 mM 
Tris-HCl Buffer was added into each well. Cells were scrapped out using a cell scraper and 
collected into ultracentrifuge tubes placed on ice. Cells were ultracentrifuged immediately to 
65,000 rpm for 30 min at 4°C. Thereafter 400 μl of the supernatant was collected from each tube 
and stored at –80°C for further assay. 
3.1.7  Bradford Assay 
Bradford assay for protein estimation content was followed by isolation of total DPP IV from 
cells. Bradford reagent was diluted from 5X to 1X using IEW. Standard curve was plotted by 
preparing different standard concentrations of 0.03125, 0.0625, 0.125, 0.25 and 0.5 mg/dl BSA. 
Ten microliter of the supernatant obtained from ultracentrifugation or the standard was mixed 
with 200 μl of 1X Bradford reagent in a 96-well plate and allowed to react for 5 minutes at 
room temperature. Thereafter absorbance was measured at 595 nm. Concentrations of the 
supernatant samples were calculated from the absorbance of the standard curve. 
3.2  Animal Experiments 
3.2.1  Animals 
Eight weeks old male C57BL/6 mice were obtained from SLC (Shizuoka, Japan) and were 
housed in standard polyacrylamide cages in SPF animal house maintained at 22±2 °C with 12-h 
light/dark cycle. All animal related ethics were followed and were approved by the Tohoku 
University Animal Ethics Committee. Animals were either kept on normal chow diet or on 
high-fat-diet as per experiment protocol and water ad libitum. Cages were changed to new ones, 
once a week. 
3.2.2  Induction of Type 1 Diabetes 
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Eight weeks mice, fed with normal chow were administered with streptozotocin at 150 mg/kg 
dissolved in citrate buffer pH 4.5. The citrate buffer was prepared immediately before use and 
streptozotocin was administered within 20 minutes of dissolving into citrate buffer. The 
injection volume was kept at less than 1% of the body weight. Blood samples were obtained on 
day 0, 2 and 7 after streptozotocin administration from tail vein. 
3.2.3 Adipocyte Isolation 
Adipocyte isolation was performed according to the method described by Thompson et al [29]. 
Abdomen of the mice was cut open after ascertaining death of the animals. Gonadal adipose 
tissue was cut out and placed in 20 ml 2% BSA-HBSS containing 0.2% collagenase. Adipose 
tissue was minced into small pieces using scissors and allowed to react with the collagenase 
solution in a rocker shaker at 120 shakes per minute, set at 37°C, for 45 min. After that time, the 
total content was filtered through 70 µm pore size filter to remove the undigested tissue and 
centrifuged at 175 xg for 5 min. At the end of centrifugation, preadipocytes and other blood 
cells settled down while the floating adipocytes were separated out using wide bore pipette tips. 
3.2.4  Adipocyte Incubation 
Twenty microliter of packed adipocytes was incubated in serum-free 5.5 or 25 mM glucose 
conditions for 24 hours. Thereafter, supernatant was collected and stored at –20°C for further 
assay. The adipocyte cells were washed in 500 μl PBS once and then collected in 500 μl 10 mM 
Tris-HCl buffer and immediately placed on ice, in ultracentrifuge tubes, for total DPP IV 
content isolation. 
3.2.5  Collection of Intracellular Content 
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Adipocytes collected in 500 μl of 10 mM of Tris-HCl buffer were ultra-centrifuged immediately 
at 130,000 xg for 30 min at 4 °C. Four hundred microliter of the supernatant was collected and 
stored at –80°C for further assay. 
3.3  Real-Time PCR 
3.3.1  Total RNA Extraction from 3T3-L1 Cells 
3T3-L1 cells were cultured in 24-well plate up to day 6 adipocytes under 5.5 or 25 mM glucose 
conditions. On day 0 and day 6, culture media was removed and adipocytes were washed with 
PBS once. Thereafter, cells were collected in 250 μl of RNA IsoPlus and stored at –80°C for 
total RNA isolation. The method of total RNA extraction is as such. 50 μl of chloroform was 
added to 250 μl of RNA IsoPlus containing cells. The tubes were shaken vigorously and were 
centrifuged at 17,600 xg for 15 minutes at 4°C. About 90–100 μl of the clear supernatant, 
containing the total RNA, was collected in a different tube, avoiding contamination with the 
DNA or protein containing layer. The supernatant was mixed with 130 μl of isopropyl alcohol 
and shaken vigorously. The tubes were then centrifuged at 17,600 xg for 15 min at 4°C. The 
isopropyl alcohol was removed carefully with the total RNA clearly visible at the bottom. The 
total RNA was then washed again in 500 μl of 75% ethanol (in DPEC) and centrifuged at 
17,600 xg for 15 minutes at 4°C. The ethanol layer was then removed carefully leaving behind 
the isolated total RNA only. The tubes were left open for about 15 minutes to allow the left 
ethanol to evaporate. The total RNA was dissolved in 25 μl of DPEC water and stored at –80°C 
for measurement of total RNA concentration. 
3.3.2  Total RNA Extraction from Animal Tissues 
Type 1 diabetes was induced in mice as described in 3.2.2. Forty-eight hours and four weeks 
after diabetes induction, animals were sacrificed under deep anesthesia and small pieces of 
different organs like liver, kidney, spleen, adipose tissue, intestine, skeletal muscle and pancreas 
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were taken out and stored in 500 μl of RNA IsoPlus at –80°C for total RNA extraction. Upon 
thawing from –80°C, tubes were subjected to homogenization at 5000 rpm, four times for 30 
seconds each. Finally total RNA was extracted as described in 3.3.1 
3.3.2  Reverse Transcription (RT) 
The total RNA concentration was measured using Nano Drop 1000. Simultaneously, the purity 
of the total RNA was evaluated by measuring optical densities at 260/280 and 260/230 nm. The 
final concentration in each tube was adjusted to be 500 ng/μl in 20 μl using DPEC water and 5X 
PrimeScript
TM
 RT Master Mix (Perfect Real Time). Reverse Transcription was carried out using 
Thermal Cycler. The protocol for reverse transcription was as such: 37°C for 15 minutes, 85°C 
for 5 seconds and then cooled down to 4°C for infinite time. 
3.3.3  Real-Time PCR 
Real-Time PCR was carried out using SYBR
®
 Premix Ex Taq
TM
 II (Tli RNaseH Plus) with 
primers specific for mice. The constitution in each PCR tube was as such: 10 μl SYBR green, 
0.5 μl of forward and reverse primer each, 7 μl of DPEC water and 2 μl of cDNA. The reactions 
were carried out as follows: 15 sec at 95 °C, 40 cycles at 95 °C for 5 sec, 60 °C for 1 min, and 
finally dissociation at 95 °C for 15 sec, 60 °C for 30 sec and 95 °C for 15 sec. Melting point 
curves were checked for defining the identity of the final product. All the genes were 
normalized to housekeeping gene peptidylprolyl isomerase A (PPIA). 
3.4  ELISA 
ELISA was carried out using DPP IV/CD26 ELISA kit. Briefly, 96-wells plate was coated with 
coating antibody overnight at 4°C. The next day, the plate was washed with wash buffer and 
blocked with 1%BSA-PBS for 1 hour at room temperature. Thereafter, wells were washed again 
with wash buffer thrice and samples and standards were added, after performing required 
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dilutions, for 2 hours.  Wells were washed again and then incubated with detecting antibody for 
2 hours. Streptavidin-HRP was added for 20 min thereafter and then substrate was added to 
obtain a blue color. The reaction was stopped after 20 min with 1 M H3PO4. Finally, absorbance 
was measured at 450 nm with correction absorbance at 570 nm. 
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4.  Results 
4.1  High-fat-diet Decreased Serum DPP IV Levels Only at Week 1 
4.1.1  High-fat-diet Increased Body Weight and Blood Glucose Levels 
Firstly, in order to understand the effect of glucose levels on serum DPP IV levels, we fed mice 
with high-fat-diet or normal chow for four weeks. Feeding with high-fat-diet maintained an 
elevated blood glucose levels. Body weight and blood glucose levels were measured on weeks 1, 
2 and 4. Clearly, mice fed with high-fat-diet for 4 weeks had an increased body weight as 
compared to those fed with normal chow (Fig. 1A). An increased adipose tissue formation was 
noted in mice fed with high-fat-diet. Furthermore, the blood glucose levels were significantly 
higher in case of high-fat-diet fed group as compared to normal chow group (Fig. 1B). The 
increase in the blood glucose levels was noted from the first week of feeding. 
 
Figure 1. Change in body weight and blood glucose levels. Male C57BL/6 mice were fed 
with normal chow and high-fat-diet for 4 weeks. (A) Change in body weight and (B) random 
blood glucose levels were determined at the end of week 1, 2 and 4. Closed circles and bars 
represent mice fed with normal chow while open circles and bars represent mice fed with high-
fat-diet. Statistical significance; ***P < 0.001, **P < 0.01, *P < 0.05 vs. corresponding normal 
chow fed mice (n= 6-8). 
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4.1.2  High-fat-diet Decreased Serum DPP IV Levels Only at Week 1 
After diabetic symptoms were ascertained from the previous experiment, we measured the 
serum DPP IV levels on weeks 1, 2 and 4. Our data shows that, mice fed with high-fat-diet had 
a significantly lower serum DPP IV levels as compared to normal chow fed mice, on week 1, 
but this difference gradually disappeared upon continuous feeding (Fig. 2A). A correlation 
graph was plotted between blood glucose levels and serum DPP IV levels on respective weeks. 
A negative correlation existed between blood glucose levels and serum DPP IV levels on week 
1, which gradually became positive up to 4 weeks (Fig. 2B).  
 
Figure 2. High-fat-diet induced lowered serum DPP IV. C57BL/6 mice were fed with normal 
chow and high-fat-diet for 4 weeks. Change in (A) serum DPP IV levels of mice fed with 
normal chow and high-fat-diet at the end of week 1, 2 and 4. (B) Correlation of serum DPP IV 
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levels and blood glucose levels at the end of respective week. Closed circles and bars represent 
mice fed with normal chow while open circles and bars represent mice fed with high-fat-diet. 
Statistical significance; ***P < 0.001, and *P < 0.05 vs. corresponding normal chow fed mice 
(n= 6-8). 
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4.1.3  Glucose Regulation of DPP IV Was Not a Short Term Process 
Since feeding with high-fat-diet increased blood glucose levels and consequently decreased 
blood glucose levels only in week 1, we tried to understand whether, serum DPP IV levels 
changes under fluctuations of blood glucose levels in day to day activity. We thus performed an 
oral glucose tolerance test (OGTT), on overnight fasted mice, for 2 hours and obtained blood 
samples from tail vein to measure the blood glucose levels and serum DPP IV. From the 
obtained data, we understood that serum DPP IV levels does not changes under the course of 
OGTT (Fig. 3A), although blood glucose levels increased as expected with the peak at 30 min 
(Fig. 3B). A non-significant decrease in serum DPP IV level was noted in the first 15 min of 
OGTT test. Hence we concluded that, the glucose regulation of DPP IV levels was not a short 
term process. Serum DPP IV does not change under day to day blood glucose levels fluctuation. 
 
Figure 3. Glucose levels did not lower serum DPP IV under OGTT conditions. Glucose (1.5 
g/kg) was orally administered to overnight-fasted normal mice. (A) Serum DPP IV and (B) 
blood glucose levels were determined at times 0, 15, 30, 60 and 120 min by drawing blood from 
the tail vein. **P < 0.01 *P < 0.05 vs. 0 min. 
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4.2  Glucose Negatively Regulated DPP IV mRNA and Protein Expression, But 
Had No Effect on Lipid Levels during Adipocyte Differentiation 
4.2.1  Oil Red O Staining of 3T3-L1 Cells Grown in 5.5 and 25 mM Glucose Conditions 
Since DPP IV is an adipokine, and is secreted from the adipocytes, we examined whether 
glucose levels could affect DPP IV levels under in-vitro conditions. Before proceeding, we 
studied the adipocyte differentiation pattern of 3T3-L1 cells when cultured in 5.5 or 25 mM 
glucose conditions. Firstly, we performed an Oil Red O staining to visualize the difference and 
also quantified the lipid levels. Obtained images (Fig. 4A) and quantified lipid levels (Fig. 4B) 
show that there was no difference in adipocyte differentiation when cultured under 5.5 or 25 
mM glucose conditions. 
 
5.5 mM 25 mM
Preadipocyte
Day 6
Day 10
A
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Figure 4. No difference in lipid levels when cultured under 5.5 or 25 mM glucose 
conditions. Differentiation of 3T3-L1 preadipocytes to adipocytes were carried out as 
mentioned in methods. Preadipocytes, Day 6 and Day 10 3T3-L1 cells were stained with Oil 
Red O. Closed bars indicate cells grown under 5.5 mM glucose and open bars indicate cells 
grown under 25 mM glucose conditions. (A) Representative images on respective days of 
adipocytes grown under 5.5 mM glucose and 25 mM glucose conditions. (B) Colorimetric 
quantification of lipid contents by Oil Red O staining. n=3. 
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4.2.2  DPP IV Activity Staining 
The expression of DPP IV was evaluated by DPP IV activity staining method. The intensity of 
redness indicated the appearance of DPP IV and related families, which increased with the 
passage of differentiation from preadipocytes to adipocytes. When cultured under 5.5 or 25 mM 
glucose conditions, there was no visual difference in the intensity of redness (Fig. 5). This 
indicated that the expression of DPP IV or other family members had no relation with the 
glucose levels. A possibility of staining of other DPP’s like Fibroblast Activating Protein (a 
surface protein like DPP IV), DPP8 and DPP9 (both intracellular) also exists as all the members 
of the DPP IV family can cleave the substrate containing Gly-Pro bond. 
 
Figure 5. DPP IV activity staining of differentiating 3T3-L1 adipocytes. DPP IV activity 
staining was performed by fixing cells in formalin: PBS: cold acetone (-20°C) = 1:35:15, grown 
under 5.5 mM glucose and 25 mM glucose conditions, followed by washing with water for 20-
30 seconds. Cells were incubated in a substrate solution constituting of glycyl-propyl-4-
methoxy-β-naphtylamide + fast blue BN for 30 minutes at room temperature, protected from 
light. Thereafter, fixed cells were washed in water for 20-30 seconds and stained with ethanol 
Preadipocytes Day 6 Day 10 Day 14
5
.5
 m
M
G
lu
co
se
2
5
 m
M
G
lu
co
se
~ 31 ~ 
 
free haematoxylin solution for 5 minutes. Representative images from preadipocytes to mature 
adipocyte are shown. 
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4.2.3  Glucose Concentrations Negatively Regulated DPP IV Levels 
The intracellular DPP IV content was determined in differentiating 3T3-L1 cells for 14 days by 
culturing cells under 5.5 and 25 mM glucose conditions. In-line with the DPP IV activity 
staining, DPP IV levels increased with differentiation. However, adipocytes cultured under 25 
mM glucose conditions produced lesser intracellular DPP IV, as compared to adipocytes 
cultured under 5.5 mM glucose conditions (Fig. 6A). The intracellular levels of DPP IV were 
normalized with the total protein levels. The released content of DPP IV was also measured by 
incubating day 10 adipocytes in serum-free media for 24 h and then measuring the DPP IV 
levels by ELISA. As similar to the results from intracellular content, the released content was 
also negatively regulated by glucose concentrations (Fig. 6B).   
 
  
0
5
10
15
20
25
30
Day 0 Day 2 Day 4 Day 6 Day 10 Day 14
In
tr
a
ce
ll
u
la
r 
D
P
P
 I
V
(p
g
/µ
g
 p
ro
te
in
)
*
*
‡‡
**
**
**
‡‡
††
†††
†††
†††
†††
A
~ 33 ~ 
 
 
Figure 6. Intracellular and released DPP IV from differentiating 3T3-L1 cells. Changes in 
(A) intracellular DPP IV protein levels during 3T3-L1 differentiation. Intracellular DPP IV 
contents were adjusted by total protein content from differentiating 3T3-L1 cells. Closed bars 
represent cells grown in 5.5 mM glucose while open bars represent that grown in 25 mM 
glucose. n=4 **P < 0.01 and 
‡‡
P < 0.01 vs. corresponding preadipocytes (day 0). 
†††
P < 0.001 
and 
††
P < 0.01 between 5.5 and 25 mM glucose. (B) Released DPP IV from day 10 adipocyte 
during 24-hour incubation in serum-free 5.5 or 25 mM glucose DMEM. n=4 
§§§
P < 0.001. 
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4.2.4  mRNA Expression of DPP IV, DPP8 and DPP9 During 3T3-L1 Adipocyte 
Differentiation 
The mRNA expression of DPP IV, DPP8 and DPP9 were compared on day 6 of 3T3-L1 
adipocyte differentiation. Differentiation of preadipocytes into adipocytes increased DPP IV 
mRNA levels, but was negatively regulated by glucose concentrations (Fig. 7, left panel). 
Although the mRNA expression of DPP8 increased but a negative regulation, like that observed 
in DPP IV, was not detected (Fig. 7, middle panel). On the other hand, the mRNA expression of 
DPP9 decreased in case of 5.5 mM glucose concentrations but remained unchanged under 25 
mM glucose concentrations (Fig. 7, right panel). These results indicated that the regulation of 
glucose on DPP IV was at the transcriptional level. 
 
Figure 7. mRNA expression of DPP IV, DPP8 and DPP9. Expression of DPP IV, DPP8 and 
DPP9 mRNA in 3T3-L1 preadipocytes and day 6 adipocytes was detected by Real-Time PCR. 
n=4. The ratio of each DPP and PPIA was calculated and the value of preadipocytes was set to 
1.0.  Closed bars represent cells grown in 5.5 mM glucose while open bars represent that grown 
in 25 mM glucose. AU= Arbitrary Units. **P < 0.01 and 
‡
P < 0.05 vs. the corresponding 
preadipocytes.  . 
†
P < 0.05, 
††
P < 0.01 between 5.5 mM and 25 mM glucose. 
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4.3  Glucose Concentration Negatively Regulated DPP IV Levels Under 
Physiological Condition But Not Under Diabetic: An ex-vivo Approach 
4.3.1  Body Weight of Mice Decreased After Streptozotocin Administration 
To clarify why negative regulation of DPP IV expression by glucose was lost in high-fat-diet 
fed mice at 4 weeks, mice was administered with streptozotocin at 150 mg/kg. As compared to 
feeding of high-fat-diet, which increases body weight and is a model for insulin resistance, 
administration of streptozotocin, induced type 1 diabetes and led to a decrease in body weight 
(Fig. 8). Decrease in the body weight was accompanied by gradual disappearance of the adipose 
tissue from the body until day 7, whereby only a negligible amount was clearly visible. 
 
Figure 8. Streptozotocin administration decreased body weight. Streptozotocin was 
dissolved in citrate buffer at a dose of 150 mg/kg. The injection volume was kept at 1% of the 
body weight. Body weight was measured at day 0 and after 7 days of streptozotocin 
administration. *P < 0.05 vs. day 0. 
  
0
5
10
15
20
25
Day 0 Day 7
B
o
d
y
 W
ei
g
h
t 
(g
)
*
~ 36 ~ 
 
4.3.2  Increased Blood Glucose Levels and Serum DPP IV Levels in Type 1 Diabetes 
Feeding of mice with high-fat-diet, which is an animal model of insulin resistance and early 
type 2 diabetes, caused slow increase in blood glucose levels. Furthermore, the serum DPP IV 
levels were lower on first week and then gradually increased. Induction of type 1 diabetes by 
streptozotocin, which causes selective destruction of pancreatic β-cells, increased blood glucose 
levels significantly from day 2. Until day 7, fasting blood glucose levels reached over four times 
the baseline levels (Fig. 9A). Increase of blood glucose levels was accompanied by increase in 
serum DPP IV levels. Serum DPP IV levels increased twice the baseline values in 7 days (Fig. 
9A). 
 
Figure 9. Increased blood glucose and serum DPP IV levels. (A) Fasting blood glucose 
levels and (B) serum DPP IV levels were determined at baseline, day 2 and day 7 after the 
injection of 150 mg/kg streptozotocin.  **P < 0.01 vs. day 0. 
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4.3.3  Intracellular and Released DPP IV Were Negatively Regulated By Glucose 
Concentrations 
Intracellular and released DPP IV content was measured by incubating 20 μl of packed 
adipocytes, isolated from mice, in serum-free 5.5 and 25 mM glucose for 24 hours. All values 
were normalized by total protein content. As consistent with the in-vitro experiments, a low 
production and release of DPP IV was observed with adipocytes incubated in 25 mM glucose 
conditions as compared to 5.5 mM glucose conditions (Fig. 10).  
 
Figure 10. Intracellular and released DPP IV under physiological conditions. Adipocytes 
prepared from control mice were incubated for 24 hours in serum-free DMEM containing 5.5 
(closed columns) or 25 mM glucose (open columns). Intracellular and released DPP IV was 
determined by ELISA. n=3 *P < 0.05 and 
†
P < 0.05 vs. the corresponding release and 
intracellular groups. 
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4.3.4  Negative Regulation of DPP IV by Glucose Was Absent Under Diabetic Conditions 
Since a negative regulation existed between glucose concentrations and DPP IV levels under 
physiological conditions, we wanted to study whether such an effect existed under diabetic 
condition. Adipocytes prepared from streptozotocin-treated mice and high-fat-diet fed mice 
were incubated under serum-free 5.5 or 25 mM glucose conditions for 24 hours. The levels of 
both intracellular and released DPP IV in adipocytes from streptozotocin-treated mice for 2 days 
were apparently higher than those from normal mice (Fig. 11A).  Furthermore, the negative 
regulation of DPP IV by glucose was not observed. The increased levels of intracellular and 
released DPP IV and lack of glucose regulation were also observed in the adipocytes prepared 
from high-fat-diet-fed mice (Fig. 11B). 
 
Figure 11. Loss of negative regulation of DPP IV by glucose in diabetic mice. Adipocytes 
prepared from (A) type 1 diabetic mice and (B) high-fat-diet fed mice were incubated for 24 
hours in serum-free DMEM containing 5.5 (closed columns) or 25 mM glucose (open columns). 
Intracellular and released DPP IV was determined by ELISA. 
†
P < 0.05 vs. between 5.5 and 25 
mM glucose. All the values were normalized with total protein levels. 
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4.3.5  Increased DPP IV mRNA Expression in Type 1 Diabetic Mice 
In order to understand, the tissues that responded to increased production of DPP IV due to 
treatment with streptozotocin, the mRNA expression of DPP IV was evaluated in several tissues 
like liver, kidney, spleen, adipose tissue, intestine, skeletal muscle and pancreas after 48 hours 
(Fig. 12A) and after 4 weeks (Fig. 12B) of administration of streptozotocin. The mRNA 
expression of DPP IV was high only in adipose tissue compared to other tissues and it remained 
high even after 4 weeks of streptozotocin administration. 
 
 
A
0
0.5
1
1.5
2
2.5
3
3.5
Liver Kidney Spleen Adipose
Tissue
Intestine Skeletal
Muscle
Pancreas
D
P
P
 I
V
 /
 P
P
IA
 m
R
N
A
 (
A
U
)
*
0
0.5
1
1.5
2
2.5
3
3.5
Liver Kidney Spleen Adipose
Tissue
Intestine Skeletal
Muscle
Pancreas
D
P
P
 I
V
 /
 P
P
IA
 m
R
N
A
 (
A
U
)
††B
~ 40 ~ 
 
Figure 12. Increased DPP IV mRNA expression in adipose tissue after streptozotocin 
administration. The levels of DPP IV mRNA in different tissues obtained normal mice (closed 
columns) and diabetic mice after 48 hours (A) and after 4 weeks (B) of STZ administration 
(open columns). *P < 0.05 and 
††
P < 0.01 vs. the corresponding control tissues. 
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4.4  TNF-α Induced DPP IV Release More Potentially Under 25 mM Glucose 
Conditions than under 5.5 mM Glucose Conditions 
4.4.1  TNF-α Induced Increased Release of DPP IV without Affecting the Intracellular 
Content in 3T3-L1 Cells 
Previous reports have shown that TNF-α levels increases under both the types of diabetes. So 
day 10 mature 3T3-L1 cells, grown under 5.5 or 25 mM glucose conditions, were stimulated 
with 10 ng/ml recombinant TNF-α for 24 h and the released and intracellular content of DPP IV 
was determined. Treatment with TNF-α induced DPP IV release, which was more apparent in 
25 mM glucose condition (Fig. 13B) although the intracellular DPP IV was less than 5.5 mM 
glucose conditions (Fig. 13A). 
 
Figure 13. Stimulation with TNF-α increased DPP IV release irrespective of glucose 
concentrations. Day 10 3T3-L1 adipocytes grown under 5.5 (closed columns) or 25 mM 
glucose conditions (open columns) were stimulated with 10 ng/ml of recombinant TNF-α for 24 
hours under serum-free conditions. (A) Intracellular and (B) released DPP IV levels were 
determined by ELISA. **P < 0.01 *P < 0.05 and 
†
P < 0.05 vs. the corresponding 5.5 mM 
control, 
‡
P < 0.05 vs. the corresponding 25 mM control. 
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4.4.2  TNF-α Also Induced Increased Release from Primary Adipocytes Irrespective of 
Glucose Concentrations 
In 3T3-L1 cells, TNF-α induced release irrespective of glucose concentrations and without 
affecting the intracellular content, so the same experiment was performed under ex-vivo 
conditions on primary adipocytes. Similar results were obtained when stimulated with 10 ng/ml 
recombinant TNF-α. TNF-α increased the release of DPP IV potentially under 25 mM glucose 
conditions as compared to 5.5 mM glucose conditions, although the intracellular content was 
not affected. The release of DPP IV from the primary adipocytes treated with recombinant TNF-
α under 25 mM glucose conditions were more than twice the controls. 
 
Figure 14. Stimulation with TNF-α increased DPP IV release irrespective of glucose 
concentrations in primary adipocytes. Isolated adipocytes incubated in 5.5 (closed columns) 
or 25 mM glucose conditions (open columns) were stimulated with 10 ng/ml TNF-α for 24 h. 
(A) Intracellular and (B) released DPP IV levels. All the values were normalized to intracellular 
total protein. *P < 0.05 **P < 0.01 and 
†
P < 0.05 vs. the corresponding 5.5 mM control, 
‡
P < 
0.05 vs. the corresponding 25 mM control. 
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4.4.3  TNF-α Did Not Affect the DPP IV mRNA Expression 
Since the release of DPP IV was increased upon stimulation with TNF-α, so the mRNA 
expression of DPP IV was analyzed. Results show that there was no change at the mRNA level 
(Fig. 15). 
 
Figure 15. Stimulation of TNF-α did not affect DPP IV mRNA expression. 3T3-L1 cells 
incubated in 5.5 (closed columns) or 25 mM glucose conditions (open columns) were stimulated 
with 10 ng/ml TNF-α for 24 h. The ratio of each DPP and PPIA was calculated and the value of 
each control was set to 1.0.  
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5. Discussion 
DPP IV, which degrades GLP-1 within minutes, is an important target of anti-diabetic treatment. 
Previous studies have shown that serum DPP IV activity increases under type 1 and type 2 
diabetes in patients and in mice. We also showed, in this study, that serum DPP IV levels were 
increased under both streptozotocin-induced and high-fat-diet induced diabetic models. A 
previous report also shows the increase in the serum DPP IV activity (but not serum DPP IV 
levels) upon feeding with high-fat-diet on rats [30]. However, the regulations of DPP IV 
production and release in physiological and diabetic condition have not been fully clarified. 
Neither was the relationship between glucose concentrations and DPP IV levels explained. Here 
we are reporting for the first time that, although DPP IV is negatively regulated by glucose in 
adipocytes under physiological conditions, such regulation was lost under diabetic conditions. 
We fed mice with high-fat-diet continuously to maintain high blood glucose levels, and 
found that serum DPP IV levels were decreased in the first week compared to the controls and 
such a difference gradually disappeared until 4 weeks. This led to a hypothesis that DPP IV is 
negatively regulated by glucose under physiological conditions. Because oral glucose treatment 
in overnight fasted mice did not affect the serum DPP IV levels, which is in line with previous 
data from patient study whereby the DPP IV activity did not change [31, 32], concluding 
negative regulation of DPP IV by glucose would be a long term process. A more recent 
evidence about the relationship between glucose levels and adipocyte DPP IV mRNA 
expression was shown by Sell et al. Clinical data suggested that a negative correlation existed 
between adipocyte DPP IV mRNA expression and glucose concentrations in normal glucose 
tolerance subjects, which is more significant in case of impaired glucose tolerance patients. 
Furthermore, a 2 h OGTT in case of normal glucose tolerance subjects showed a positive 
correlation between glucose levels and adipocyte DPP IV, whereas a small non-significant 
negative correlation was observed in case of impaired glucose tolerance patients [23]. However, 
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such a negative correlation in case of OGTT was not observed in case of our animal 
experiments. From these series of experiments we concluded that, the glucose regulation of DPP 
IV is not a short-term process, and serum DPP IV level does not vary from day to day glucose 
fluctuations. One of the possibilities that exist is DPP IV levels decreases under a prolonged 
high glucose condition, and then increases gradually, once the negative correlation is lost, 
leading to diabetic conditions. 
Previous reports have indicated that the increase in weight of adipose tissue causes 
increase in serum DPP IV levels. Therefore, we particularly focused on adipocytes as DPP IV is 
an adipokine. 3T3-L1 preadipocytes expressed only a small amount of DPP IV but, during the 
process of differentiation to mature adipocytes, increase in intracellular contents and mRNA 
expression of DPP IV were observed. The differentiation-dependent expression of DPP IV in 
adipocytes was also observed in human primary adipocytes [13]. Furthermore, in this study, 
we found that the differentiation-dependent increase in intracellular DPP IV was negatively 
regulated by glucose concentrations without affecting adipocyte differentiation. Mature 
adipocytes obtained from normal mice also showed that 25 mM glucose decreases intracellular 
and released DPP IV in 24-hour incubation. These findings suggested that mature adipocyte 
produced DPP IV and the production was negatively regulated by glucose as consistent with the 
observation that high-fat-diet induced reduction of serum DPP IV levels at week 1.  
The expression of DPP IV mRNA from 3T3-L1 adipocytes was first reported by 
Rosmaninho-Salgado et al [33]. In parallel to that report, we showed the expression pattern of 
DPP IV from preadipocytes to adipocytes. Among DPP IV, DPP8 and DPP9, only DPP IV was 
negatively regulated by glucose.  Although an increase in the mRNA expression of DPP8 was 
observed, but a negative correlation that existed in mRNA expression of DPP IV was missing. 
On the other hand, the mRNA expression of DPP9 went lower. One of the possible reasons for 
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this down-expression is that, overexpression of DPP9 leads to poor cell adhesion as shown in 
HEK293 cells [34].  
Negative regulation of DPP IV by glucose has already been reported in intestinal cell 
line CaCo-2 [15].  Glucose concentrations negatively regulate the expression of a transcriptional 
factor called Hepatocyte Nuclear Factor-1α (HNF-1α) and this in turn regulates DPP IV. 
Expression of dominant negative HNF-1α reduced DPP IV production in CaCo-2 cells. 
However, the involvement of HNF-1α in DPP IV expression in adipocytes has not been 
established. The expression of HNF-1α mRNA in adipocytes was very low, indicating another 
regulation would be existed in adipocytes. The activity staining DPP IV on 3T3-L1 adipocytes 
merely indicates the expression of DPP IV and related families increases with the differentiation. 
However, since this method is a qualitative test, so possibility of other DPP IV members like the 
fibroblast activating protein being stained cannot be ruled out. A number of possible grounds 
were analyzed to understand the negative regulation under physiological conditions, but didn’t 
provide any positive results. Protein channels, transcription factors, phosphatases and kinases 
were targeted and treated with their agonists and antagonists to understand the mechanism. 
cAMP levels were measured under 5.5 and 25 mM glucose conditions as one of the previous 
report showed a difference in cAMP levels under 5.5 and 25 mM glucose condition [35]. 
However, the cAMP levels were same in adipocytes cultured under two glucose conditions. 
Furthermore, TRPV4 channels, that are known to be regulated by glucose [36] and are being 
expressed by adipose tissue [37] were also treated with their agonists and antagonists. However, 
results were negative. We also focused on certain pathways like the JAK-STAT, which has been 
shown to be regulated by glucose levels in glomerular cells [38] but came to be negative. Cells 
were also stimulated for MAPK [39, 40] and AMPK inhibitors but no positive results were 
found. 
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Under diabetic conditions, whether glucose still negatively regulated DPP IV 
production was a matter of interest. An increase in weight of the adipose tissue increases DPP 
IV levels, as suggested by previous reports [13]. Actually, the increase in adipose tissues, as 
indicated by the increase in body weight, in high-fat-diet-fed mice was correlated to the lack of 
glucose regulation of DPP IV.  A positive correlation between the glucose adipocyte size and 
serum DPP IV levels has already been established [13, 23]. However, in streptozotocin-induced 
diabetes model, DPP IV levels are also increased although the body weight is decreased.   Thus, 
although we could not deny that the increase in adipocytes caused the increase in DPP IV levels 
in high-fat-diet-fed mice; diabetic condition also affected DPP IV production independent of the 
size of adipocytes. Determination of DPP IV mRNA levels in tissues of streptozotocin-treated 
mice disclosed that adipose tissue was the only tissue to produce increased levels of DPP IV at 
the first 48-hour, which remained high up to 4 weeks of streptozotocin administration. Although 
after 7 days, the amount of adipose tissue declined rapidly and it was impossible to isolate 
adipocytes from it, still a small portion of adipose tissue was clearly visible and was extracted 
for mRNA analysis. In addition, the intracellular DPP IV levels of adipocytes collected from 
both streptozotocin-and high-fat-diet-treated mice are apparently higher than those from normal 
mice, indicating that negative regulation by glucose of DPP IV production in adipocytes was 
lost under diabetic condition. The increased production of DPP IV activity from adipocytes in 
diabetic condition was also supported by Kirino et al. [41].  One probable reason is that 
deficiency of insulin in type 1 diabetic conditions induced low availability of glucose in 
adipocytes, resulting in lack of glucose-induced negative signaling. In case of insulin-resistant 
conditions, the circulating insulin in blood was unable to utilize the available glucose in blood 
and thus the adipocytes constantly sensed a low glucose condition inside the cell, in turn 
producing more intracellular DPP IV. 
There have been earlier reports that TNF-α levels are increased under both 
streptozotocin-induced type 1 [42] and high-fat-diet induced type 2 diabetes [43]. There also 
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have been reports in which stimulation with TNF-α increased DPP IV activity in human 
umbilical vein endothelial cells [44].  We confirmed that TNF-α induced the release of DPP IV 
from the 3T3-L1 adipocytes and isolated mice adipocytes.  Importantly, TNF-α induced release, 
was not reduced in 25 mM glucose concentrations but rather increased as compared to 5.5 mM 
glucose concentrations. Furthermore, the mRNA expression and intracellular levels of DPP IV 
did not change, indicating that stimulation with TNF-α had no effect at transcriptional and 
translational levels, but only affected the extracellular surface DPP IV. One of the possible 
reasons might be the shedding of surface DPP IV induced by TNF-α irrespective of glucose 
concentrations. In our experimental setup, we tried to measure serum TNF-α levels after 
administration of streptozotocin. However, although type 1 diabetes was induced in those mice, 
which was ascertained by increased fasting blood glucose levels and serum DPP IV levels, 
serum TNF-α could not be detected in our system. Therefore, further studies are required to 
clarify the involvement of TNF-α locally produced in adipose tissues in DPP IV increase in our 
models. 
Glucose regulation of DPP IV in physiological conditions is a reasonable response 
because high glucose induces the decrease in the levels of DPP IV, in turn, increase in the levels 
of GLP-1, resulting in enhancement of insulin release and responses to lower the serum glucose 
levels. The lowering of serum DPP IV on the first week is an indication that body might 
respond in manner to produce increased GLP-1 to produce more insulin and thereby counteract 
increased blood glucose levels. The loss of the glucose regulation of DPP IV in diabetic 
condition might be a vicious spiral of intractable diabetes.  
In conclusion, our results suggest that DPP IV levels are negatively regulated by 
glucose concentrations in adipocytes under physiological conditions, but the regulation was lost 
under diabetic conditions probably via a low availability of glucose. Increased production of 
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DPP IV from the adipocytes and TNF-α induced release of DPP IV from adipocytes can be 
attributed to the increased serum DPP IV levels under both type 1 and II diabetes. 
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Figure 16. Summary and hypothesis of this study. (A) DPP IV levels are negatively regulated 
by glucose concentrations in adipocytes under physiological conditions (1). However under 
diabetic conditions, the regulation was lost with increased blood glucose and DPP IV levels (2). 
We observed an increased DPP IV production from the adipocytes which contributed to serum 
DPP IV levels (3). Furthermore, under diabetic conditions serum TNF-α levels increases (4) and 
this leads to an increased release of DPP IV from the adipocytes (5). (B) Glucose regulation of 
DPPIV in physiological conditions is a reasonable response because high glucose induces the 
decrease in the levels of DPPIV, in turn, increase in the levels of GLP-1, resulting in 
enhancement of insulin release and responses to lower the serum glucose levels. We believe that 
this negative regulation of DPP IV gets lost under diabetic conditions and leads to diabetes. 
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